


05-03-00

GAU 1614
SEQ. BOX W



CERTIFICATE OF MAILING BY "EXPRESS MAIL"
UNDER 37 C.F.R. § 1.10

RECEIVED RECEIVED

"Express Mail" mailing label number: EK441166439US
Date of Mailing: May 1, 2000

MAY 10 2000 MAY 05 2000

TECH CENTER 1600/2000

I hereby certify that this correspondence is being deposited with the United States Postal Service, utilizing the "Express Mail Post Office to Addressee" service addressed to **Assistant Commissioner for Patents, Washington, DC 20231** and mailed on the above Date of Mailing with the above "Express Mail" mailing label number.

Tracy L. Morton (Signature)
Tracy L. Morton
Signature Date: May 1, 2000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application)	<u>PATENT APPLICATION</u>
)	
Inventor(s): Hermiston et al.)	Art Unit: 1614
)	
SC/Serial No.: 09/472,691)	
)	
Filed: December 27, 1999)	
)	
Title: Adenovirus E1B Shuttle Vectors)	
)	

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Assistant Commissioner for Patents
Washington, DC 20231

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, dated February 5, 2000, enclosed are the following documents in connection with the above-identified application:

[X] Copy of Notice.

[X] Sequence Listing (Paper and CRF copies).


[X] Preliminary Amendment.

[X] The Commissioner is hereby authorized to charge any fees associated with this communication, *including* extension of time fees that may be due, to Deposit Account No. 15-0615. A duplicate copy of this authorization is enclosed.

Respectfully submitted,

Dated: May 1, 2000

By: _____


Gregory Giotta
Reg. No. 32,028

ONYX Pharmaceuticals, Inc.
3031 Research Drive
Richmond, California 94806
Telephone (510) 222-9700



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARK
Washington, D.C. 20231

APPLICATION NUMBER 097472,691	FILING/RECEIPT DATE 12/27/99	FIRST NAMED APPLICANT HERMISTON	ATTORNEY DOCKET NO./FEE
----------------------------------	---------------------------------	------------------------------------	-------------------------

FEB 10

MAY 1 2000

0242/0205

GREGORY GIOTTA PH.D.
VICE PRESIDENT AND CHIEF LEGAL COUNSEL
ONYX PHARMACEUTICALS INC
3031 RESEARCH DRIVE
RICHMOND CA 94806

1614

02/05/00

DATE MAILED:

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

An Application Number and Filing Date have been assigned to this application. The items indicated below, however, are missing. Applicant is given TWO MONTHS FROM THE DATE OF THIS NOTICE within which to file a sequence listing in compliance with 37 CFR 1.821 - 1.825 to avoid abandonment. Extensions of time may be obtained by filing a petition accompanied by the extension fee under the provisions of 37 CFR 1.136(a).

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application fails to comply with the requirements of 37 CFR 1.821 - 1.825.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 CFR 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ☐ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
- ☐ 7. OTHER:

APPLICANT MUST PROVIDE:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing."
- ☒ An initial or substitute paper copy of the "Sequence Listing," as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CONTACT:

- ☒ For Rules Interpretation, call (703) 308-1123.
- ☒ For CRF submission help, call (703) 308-4212.
- ☒ For PatentIn software help, call (703) 308-6856.

[Handwritten signature]

Customer Service Center

1022
U.S. Pat. & Tm.
4/5/00
1/5/00
GL
On